Sun Nelson's Form 4 filing
Aardvark Therapeutics, Inc. (AARD) · filed Sep 11, 2026
- Accession no.
- 0001193125-26-389564
- Filed
- Sep 11, 2026, 8:14 PM ET
- Trade date
- Sep 10-11, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $395.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sun NelsonCIK 0002045377 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Common Stock, par value $0.00001 per share | SSaleDisposed | −14,754 | $5.00F2 | −$73,778.85 | 97,475 | Direct | |
| Sep 11, 2026 | Common Stock, par value $0.00001 per share | SSaleDisposed | −62,000 | $5.18 | −$321,178.6 | 35,475 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Financial & Operating Officer